3Me6,7MDTIQ

3Me6,7MDTIQ
Clinical data
Other names	3-Methyl-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline; 3-MMOTI
ATC code	None;
Identifiers
	IUPAC name 7-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline;
CAS Number	151109-51-2;
PubChem CID	42684;
ChemSpider	38934;
CompTox Dashboard (EPA)	DTXSID00934174 ;
Chemical and physical data
Formula	C11H13NO2
Molar mass	191.230 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CC2=CC3=C(C=C2CN1)OCO3;
	InChI InChI=1S/C11H13NO2/c1-7-2-8-3-10-11(14-6-13-10)4-9(8)5-12-7/h3-4,7,12H,2,5-6H2,1H3; Key:BGKYNZFHWPNVJF-UHFFFAOYSA-N;

3Me6,7MDTIQ, also known as 3-methyl-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline, is a drug of the phenethylamine and tetrahydroisoquinoline families related to the psychedelic and entactogen drug 3,4-methylenedioxyamphetamine (MDA).^[1] It is a cyclized phenethylamine and is a known active metabolite of MDA in rodents.^[1] In contrast to MDA however, 3Me6,7MDTIQ shows different pharmacological effects, for instance producing hypolocomotion instead of hyperlocomotion.^[1] The chemical synthesis of 3Me6,7MDTIQ has been described.^[1] 3Me6,7MDTIQ was first described in the scientific literature in 1993.^[1]